A German Biotech Just Secured $6.5M to Target a Hidden Driver of Heart Disease

Jan de Vries · 2026-08-28

Let's talk about what's happening in Heidelberg. A new biotech player, Revier Therapeutics, just stepped onto the field with a serious mission: tackling some of the toughest heart and metabolic diseases. And they didn't come empty-handed. They've closed a Seed financing round worth about $6.5 million (that's roughly €6 million converted) to back their ambitious science. It's a significant vote of confidence from a savvy investor group. The round was led by the KHAN Technology Transfer Fund II, with key participation from High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg. ### The Unmet Need in Heart Health You'd think with all our medical advances, we'd have heart disease figured out. But the reality is, millions of patients are still stuck with limited options. Prof. Eva van Rooij, PhD, Revier's CEO, put it bluntly. She points to conditions like HFpEF (heart failure with preserved ejection fraction) and ASCVD (atherosclerotic cardiovascular disease). Despite progress, targeted treatments are scarce. The company's bet is that the next wave of medicine needs to go deeper. It's not just about managing symptoms. It's about hitting the underlying biological mechanisms that drive the disease in the first place. That's a much taller order, but the potential payoff for patients is huge. ### A More Precise Approach to HDACs Here's where the science gets interesting. Revier is going after something called class IIa histone deacetylases, or HDACs. Don't let the jargon scare you. Think of HDACs as enzymes—tiny cellular machines—that play a role in serious diseases. The first-generation drugs that targeted HDACs were a bit like using a sledgehammer. They hit multiple classes, which often led to nasty side effects that limited how much medicine a patient could take. Revier's strategy is all about precision. Their orally available small molecules are designed to be snipers, not bombers. - They aim to selectively inhibit only the class IIa HDACs. - The goal is to block the disease-causing activity while leaving healthy, essential functions alone. - This approach could mean effective treatment without the harsh side effects that plagued earlier attempts. Prof. Johannes Backs, MD, the company's scientific founder, explained that this precision is what could make their therapy a game-changer. It's designed to be both therapeutically potent and safer. ### What the Investors Are Saying So why are investors excited? Michael Hamacher, PhD, from KHAN Technology Transfer Fund II, sees Revier's work as a key to unlocking the true therapeutic promise of HDAC biology. He believes their differentiated strategy, combined with a top-tier leadership team, gives them a unique shot at delivering drugs that don't just treat but actually modify the course of disease. The aim is to reshape the standard of care for patients with HFpEF, ASCVD, and related disorders. ### Where the Funding is Headed That $6.5 million seed capital has a clear job. Revier plans to pour it into advancing its preclinical pipeline. The main focus is on two programs: 1. Their lead program targeting HFpEF. 2. A second program for ASCVD. The money will also help them build out the operational, scientific, and clinical teams needed to move from the lab toward human trials. It's a classic biotech story: brilliant science meets strategic funding, all aimed at solving a massive human problem. For anyone watching the European startup scene, especially in life sciences, this is one to keep an eye on.